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Abstract
Background: Menstrual migraine and menstrually related migraine attacks are typically longer, more disabling,
and less responsive to medications than non-menstrual attacks. The aim of this study was to evaluate the efficacy,
safety, and tolerability of non-invasive vagus nerve stimulation for the prophylactic treatment of menstrual
migraine/menstrually related migraine.
Methods: Fifty-six enrolled subjects (menstrual migraine, 9 %; menstrually related migraine, 91 %), 33 (59 %) of
whom were receiving other prophylactic therapies, entered a 12-week baseline period. Fifty-one subjects subsequently
entered a 12-week treatment period to receive open-label prophylactic non-invasive vagus nerve stimulation
adjunctively (31/51; 61 %) or as monotherapy (20/51; 39 %) on day −3 before estimated onset of menses through
day +3 after the end of menses.
Results: The number of menstrual migraine/menstrually related migraine days per month was significantly
reduced from baseline (mean ± standard error, 7.2 ± 0.7 days) to the end of treatment (mean ± standard error, 4.7
± 0.5 days; P < 0.001) (primary end point). Of all subjects, 39 % (95 % confidence interval: 26 %, 54 %) (20/51) had
a ≥ 50 % reduction (secondary end point). For the other secondary end points, clinically meaningful reductions in
analgesic use (mean change ± standard error, −3.3 ± 0.6 times per month; P < 0.001), 6-item Headache Impact Test
score (mean change ± standard error, −3.1 ± 0.7; P < 0.001), and Migraine Disability Assessment score (mean
change ± standard error, −11.9 ± 3.4; P < 0.001) were observed, along with a modest reduction in pain intensity
(mean change ± standard error, −0.5 ± 0.2; P = 0.002). There were no safety/tolerability concerns.
Conclusions: These findings suggest that non-invasive vagus nerve stimulation is an effective treatment that
reduces the number of menstrual migraine/menstrually related migraine days and analgesic use without
safety/tolerability concerns in subjects with menstrual migraine/menstrually related migraine. Randomised
controlled studies are warranted.
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Background
Menstrual migraine (MM) without aura is defined as the
exclusive occurrence of attacks on days −2 to +3 of men-
struation in at least 2 of 3 consecutive menstrual cycles
according to the International Classification of Head-
ache Disorders, 3rd edition (beta version) (ICHD-III beta)
appendix (i.e., requires further validation), and menstru-
ally related migraine (MRM) without aura is also charac-
terized by the occurrence of attacks on other days of the
cycle [1]. More than 90 % of women with migraine
attacks during menstruation have MRM [2]; the esti-
mated prevalence among migraineurs has varied from
0.85 to 14.1 % for MM and from 3 to 71.4 % for MRM
[3]. These conditions are believed to be a result of fluc-
tuating oestrogen levels; steady or elevating levels are
associated with a protective effect, whereas abrupt
oestrogen withdrawals are associated with precipitation
of migraine attacks [2, 4]. In the late luteal phase of the
menstrual cycle, decreased oestrogen levels have been
observed, which lead to serotonin declines and are likely
responsible for the triggering of MM/MRM attacks just
prior to menses [2, 4].
No acute or prophylactic therapies are currently ap-
proved specifically for the treatment of MM/MRM in
the European Union or the United States [5, 6]. Acute
treatments used for these conditions are the same as
those used for non-menstrual migraine and include trip-
tans, non-steroidal anti-inflammatory drugs (NSAIDs),
and ergot derivatives [2, 6]. Prophylaxis comprises short-
term and continuous treatments [2]. Short-term prophylac-
tic therapies are administered only during the time of need
(e.g., perimenstrually) and include triptans, oestrogen, and
naproxen, whereas continuous prophylactic options such
as hormonal contraceptives provide ongoing exposure to
the treatment [2]. A systematic review of MM/MRM
clinical trials indicated that evidence supporting most
categories of prophylactic MM/MRM treatments is
generally weak [6]. Clinical studies of triptans represent
the strongest evidence to date for acute and preventive
MM/MRM treatment, which supports almotriptan, nar-
atriptan, sumatriptan, and zolmitriptan as acute therap-
ies and frovatriptan, naratriptan, and zolmitriptan as
preventive therapies [6].
Despite the general safety and tolerability of triptans
with appropriate patient selection [2, 7, 8], the MM/
MRM population may have unique challenges related to
the adverse events (AEs) associated with these treat-
ments. Compared with non-menstrual migraine attacks,
MM/MRM attacks are generally longer lasting, more de-
bilitating, more prone to recurrence, and less responsive
to therapies such as triptans [9, 10]. Results from a large
study showed that 44 % and 48 % of migraineurs were
dissatisfied with triptan-associated tolerability and gen-
eral/work-related functional ability, respectively [7], and
these concerns may be even more prominent in the rela-
tively treatment-refractory MM/MRM population [10].
Menses is generally considered to be a period of inher-
ent discomfort [11], and the repeated treatments
required to mitigate the effects of MM/MRM could fur-
ther exacerbate the level of discomfort while providing
only minimal response [10, 12]. Evidence-based guide-
lines for migraine suggest limiting the use of triptans to
2 headache days per week to reduce the risk of rebound
or medication-overuse headache [8], and frequent use of
these agents may lead to misuse/overuse and has been
significantly associated with the development of chronic
migraine [13, 14]. Thus, the prophylactic administration
of triptans over the course of several days during men-
struation coupled with the potential need for acute trip-
tan therapy in women with MM/MRM could complicate
the condition [12, 13]. Patients may be unwilling to
accept the AE burden and/or potential complications of
adhering to monthly prophylactic MM/MRM therapies
[15], defining a need for alternative treatment options
among this population.
Non-invasive vagus nerve stimulation (nVNS) (gamma-
Core®; electroCore, LLC; Basking Ridge, NJ, USA) provides
neuromodulation that transfers electrical impulses
transcutaneously to the cervical branch of the vagus
nerve. In 4 open-label ≤ 12-week studies, nVNS demon-
strated efficacy, safety, and tolerability as an acute/
prophylactic therapy for migraine and chronic cluster
headache [16–19]. Based on the treatment benefits ob-
served in previous studies and the potential for
reducing medication overuse and medication-associated
AEs [16], we evaluated nVNS used as mini-prophylaxis
for MM/MRM in this 24-week study of 56 subjects.
Methods
Study design
This investigator-initiated, multicentre, single-arm,
open-label study of the efficacy, safety, and tolerability
of prophylactic nVNS treatment for MM/MRM was
conducted from January 2015 to October 2015. After
providing informed consent for trial participation and
publication of patient data, subjects entered a 12-week
run-in (baseline) period of observation followed by a
12-week nVNS treatment period to receive open-label,
short-term MM/MRM prophylaxis. Investigators ob-
tained approval from the Ethical Committees of the
Istituto di Ricovero e Cura a Carattere Scientifico
(IRCCS), San Raffaele Pisana (identifier: SR_MM12/
2014). All source documents and files are stored in the
clinical trial centres.
Subjects
All subjects were enrolled from two Italian sites and were
required to have a regular menstrual cycle. Inclusion
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criteria specified that subjects were to be 18 to 50 years of
age. Subjects had a > 1-year history of migraine with or
without aura and a diagnosis of MM/MRM without aura
according to ICHD-III beta criteria [1]. Key exclusion
criteria at the time of enrolment were another diagnosis
of a primary headache disorder, such as chronic mi-
graine, secondary headache disorder, or other neuro-
logical or severe systemic disease; current or previous
vagal disturbances; a change in prophylactic medication
type or dosage within 1 month before enrolment; previ-
ous failure of ≥ 3 prophylactic treatment classes; and
participation in another clinical trial.
Intervention
The nVNS devices (Fig. 1) for this study, supplied by
electroCore, LLC, produce a proprietary low-voltage
electrical signal comprising a 5-kHz sine wave burst last-
ing for 1 millisecond (five sine waves, each lasting 200
microseconds), with such bursts repeated once every 40
milliseconds (25 Hz), generating a 24-V peak voltage
and 60-mA peak output current. Subjects received com-
prehensive training on appropriate device placement and
adjustment of stimulation intensity for optimal dose
administration. Bilateral 2-min stimulations were admin-
istered to the cervical branch of the vagus nerve 3 times
daily at 8 AM, 1 PM, and 8 PM (i.e., 6 stimulations total per
day) after application of conductive gel to the 2 stainless
steel contact surfaces. This procedure was performed
from −3 days before estimated onset of menstruation
through +3 days after the end of menstruation during
each cycle of the 12-week nVNS treatment period.
Treatment duration per month in this study was 10 to
14 days based on the actual days of menstruation. Doses
of any prophylactic medications were kept stable
throughout the study. Subjects were allowed to use their
usual acute analgesics (alone or in combination), which
included triptans, NSAIDs, and a butalbital/caffeine/pro-
pyphenazone combination medication.
Study end points
The primary end point was the mean change in number
of MM/MRM days per month between the baseline and
nVNS treatment periods. Secondary end points included
the proportion of subjects with a ≥ 50 % reduction in the
mean number of MM/MRM days from the baseline
period to the nVNS treatment period and mean changes
between the two study periods in analgesic use, migraine
disability, pain intensity, and allodynia. Exploratory ana-
lyses of proportions of subjects who achieved various
levels of improvement in migraine disability were also
performed.
Data collection
At baseline, subjects underwent a physical and neuro-
logical examination and a live interview administered via
a detailed, semistructured questionnaire on their 1) clin-
ical migraine features; 2) demographics, lifestyle, and
behavioural factors; and 3) comorbidities and concomi-
tant medications [20]. During the study periods, subjects
used diary cards to record their MM/MRM days and an-
algesic use on a daily basis. This information was used
to calculate monthly averages for each 3-month study
period. Data on migraine disability were collected using
the 6-item Headache Impact Test (HIT-6™) [21] based
on the last 4 weeks of each study period and the MIDAS
based on the entire 3 months of each study period [22].
Scores on the HIT-6 range from 36 to 78 points, MIDAS
scores range from 0 to 21+ points, and MIDAS grades
range from 1 to 4, with higher values indicating greater
disability for each of these assessments [21, 22]. Pain in-
tensity for each migraine attack was rated using question
B of the Migraine Disability Assessment (MIDAS) on a
scale from 0 to 10, with higher values indicating greater
intensity, and was averaged at the end of each 3-month
study period [22]. Data on allodynia were collected using
the 12-item Allodynia Symptom Checklist (ASC-12),
with scores ranging from 0 to 24 points and higher
scores indicating greater severity [23]. The investigator
collected safety and tolerability data by asking partici-
pants to provide subjective responses at each study visit
regarding any AEs after nVNS use.
Statistical analyses
Subjects who received at least 1 nVNS treatment were
included in the intent-to-treat (ITT) population for effi-
cacy analyses. Mean ± standard error of the mean (SEM)
changes between the two study periods were calculated
using data from week 12 of the nVNS treatment period
minus data from the baseline visit, with negative values
indicating a decrease over time. Two-sided statistical
Fig. 1 Non-invasive Vagus Nerve Stimulation Device. Image provided
courtesy of electroCore, LLC
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analyses were conducted using a significance level of P <
0.05; P values were derived from the t test. The exact
Clopper-Pearson method was used to calculate the 95 %
confidence interval (CI) for the proportion of subjects
with a ≥ 50 % reduction in mean number of MM/MRM
days between the two study periods. Missing data were
imputed using the last observation carried forward
method. Data for subjects who discontinued during the
nVNS treatment period were imputed to baseline values
and were included in all efficacy analyses, whereas subjects
with missing data for both study periods were not included
in the analyses. All statistical analyses were performed in-
dependently by North American Science Associates Inc.
(Minneapolis, MN, USA) using SAS® 9.3 (SAS Institute
Inc., Cary, NC, USA).
Results
Subjects
Of the 56 subjects screened, all were enrolled and
entered the baseline period, including 6 subjects who
were older than 50 years of age but met all other entry
criteria. All subjects were diagnosed with MM/MRM
without aura and had episodic migraine at enrolment.
Demographic and baseline characteristics (Table 1)
showed a mean age of 40.2 years. Most subjects had
MRM (91 %), and the remaining 9 % had MM. For 7
subjects, the average number of headache days per
month in the baseline period had increased to a range
of 15 to 20 days; this increase was not sustained for
more than 3 months, thereby excluding a diagnosis of
chronic migraine. Five subjects discontinued from the
study before entering the nVNS treatment period, in-
cluding 2 subjects who became pregnant, 1 subject
who entered menopause, 1 subject who underwent
surgery, and 1 subject for whom no reason for study
withdrawal was provided. The remaining 51 subjects
met criteria for the ITT population. Of these, 5 sub-
jects discontinued from the nVNS treatment period
because of lack of efficacy, and 1 subject discontinued
because of non–device-related AEs.
Menstrual/Menstrually related migraine days
Therapy with nVNS significantly reduced the mean
number of MM/MRM days (primary end point) from
baseline (7.2 ± 0.7 days) to the end of the treatment
period (4.7 ± 0.5 days; P < 0.001) (Fig. 2). During the
nVNS treatment period, 39 % (95 % CI: 26 %, 54 %) of
all subjects (20/51) had a ≥ 50 % reduction in the mean
number of MM/MRM days from baseline.
Analgesic use
Mean analgesic use was significantly reduced from
8.9 ± 0.8 times per month in the baseline period to
5.6 ± 0.5 times per month in the nVNS treatment
period (P < 0.001) (Fig. 3).
Migraine disability
A reduction in migraine disability was demonstrated by
the mean HIT-6 score being significantly improved from
baseline (67.2 ± 0.7) to the end of the nVNS treatment
period (64.1 ± 0.7; P < 0.001) (Fig. 4). This improvement
of 3.1 exceeds the estimated minimally important differ-
ence (MID) of 2.3 to 2.7 that has been established as
clinically meaningful [21].
Significant improvements after nVNS treatment were
also observed for MIDAS score (baseline, 42.2 ± 4.7;
nVNS, 30.3 ± 3.3; P < 0.001) (Fig. 5a) and MIDAS grade
(baseline, 3.6 ± 0.1; nVNS, 3.3 ± 0.1; P = 0.008) (Fig. 5b).
Table 1 Demographic and Baseline Characteristicsa
Characteristic Total Population
(n = 56)
Age (y), mean ± SEM 40.2 ± 1.0
Age of onset (y), mean ± SEM 17.9 ± 1.3
Currently employed, No. (%) 49 (88)
Migraine type, No. (%)
MRM 51 (91)
MM 5 (9)
Pain location, No. (%)
Bilateral 17 (30)
Unilateral 39 (70)
Average duration of untreated/unsuccessfully
treated attacks, No. (%)
< 12 h 2 (4)
12 to < 24 h 15 (27)
24 to < 48 h 7 (13)
48 to < 72 h 14 (25)
≥ 72 h 18 (32)
Analgesic medications used, No. (%)
NSAID 17 (30)
NSAID plus triptan 20 (36)




Other prophylactic medication use, No. (%)b 33 (59)
Abbreviations: MM, menstrual migraine, MRM menstrually related migraine,
NSAID nonsteroidal anti-inflammatory drug, nVNS non-invasive vagus nerve
stimulation, SEM standard error of the mean
aData represent values from the baseline period
bAmitriptyline (5/56), coenzyme Q10/ginkgolide B/riboflavin (tablets) plus
magnesium (4/56), coenzyme Q10/ginkgolide B/riboflavin/magnesium
(granulated) (1/56), coenzyme Q10/ginkgolide B/riboflavin/magnesium
(granulated) plus amitriptyline (1/56), magnesium (3/56), β-blocker (2/56),
calcium channel blocker (2/56), paroxetine (2/56), riboflavin (2/56), amitriptyline
plus benzodiazepine (1/56), amitriptyline plus magnesium (1/56), β-blocker plus
amitriptyline (1/56), botulinum toxin A (1/56), sodium valproate plus venlafaxine
(1/56), sodium valproate plus paroxetine (1/56), tanacetum parthenium (1/56),
sertraline (1/56), topiramate plus sertraline (1/56), topiramate plus gabapentin (1/56)
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Pain intensity
Mean pain intensity demonstrated a clinically modest
reduction from baseline (7.6 ± 0.2) to the end of the
nVNS treatment period (7.1 ± 0.2; P = 0.002) (Fig. 6).
Allodynia
Allodynia scores during the treated migraine attacks were
similar between the two study periods, with a mean differ-
ence of 0.2 ± 0.4 between the baseline period (5.4 ± 0.7)
and the nVNS treatment period (5.5 ± 0.8; P = 0.58).
Safety and tolerability
There were no safety concerns during the study. The
most commonly self-reported AEs were mild or moder-
ate application site reactions (e.g., tingling) and facial/
neck twitching. These AEs were transient in nature, co-
incided with the stimulation period, and resolved dur-
ing treatment. No serious AEs occurred. Only 1 subject
discontinued from the nVNS treatment period because












































Fig. 2 Change in Number of MM/MRM Days per Month (ITT Population)a. Abbreviations: ITT, intention-to-treat; nVNS, non-invasive vagus nerve
stimulation; SEM, standard error of the mean. aData are mean ± SEM; mean differences between treatment groups may not reflect calculated

















































Fig. 3 Change in Analgesic Use per Month (ITT Population)a. Abbreviations: ITT, intention-to-treat; nVNS, non-invasive vagus nerve stimulation;
SEM, standard error of the mean. aData are mean ± SEM; mean differences between treatment groups may not reflect calculated differences
because of rounding; P values are from the t test; missing data were imputed using the last observation carried forward
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Discussion
To our knowledge, this study is the first to evaluate the
effects of a neuromodulation device for the treatment of
MM/MRM without aura. Primary end point results
demonstrated that prophylactic nVNS administered
from −3 days before estimated onset of menstruation
through +3 days after the end of menstruation (a total of
10 to 14 days of treatment per month) for 3 cycles pro-
vided an average decrease of 2.4 MM/MRM days per
month (~33 %), which exceeds the MID of 1 headache
day established for this end point [24, 25]. The change
in number of headache days from baseline is among the
few headache-symptom measures with an established
MID, and this MID has been associated with significant
effects on health-related quality of life [24, 25]. The as-
sessment of MM/MRM days for the primary end point
is clinically relevant to patients and treating physicians,
acknowledging that we did not concurrently assess the
frequency of individual attacks in this initial study of
MM/MRM prophylaxis. The reduction in MM/MRM
days was accompanied by significant and clinically
meaningful reductions in analgesic use and functional
disability. Although this prophylactic study was not
intended to evaluate the efficacy of nVNS in the acute
treatment of attacks, a modest decrease in pain inten-
sity was observed for the attacks that were not pre-
vented. As several end points in this study represent
monthly averages during each 3-month study period,
the possibility for improvements in actual monthly
MM/MRM outcomes with nVNS treatment over time
warrants further evaluation.
Study limitations include the open-label, single-arm
study design and the potential for inaccurate subject
predictions of menses onset. The open-label study de-
sign likely contributed a placebo response to the treat-
ment, as seen in other therapeutic migraine studies
[18, 26]. In this study, the actual treatment effect of
nVNS cannot be separated from the potential placebo
effect because of the lack of a sham control group. On
the basis of the ease of use and lack of AE concerns
associated with nVNS in the current study, the device
appears to have a favourable risk-benefit profile in
MM/MRM that is appropriate for further evaluation.
As in any MM/MRM study of prophylaxis, imprecise
treatment initiation due to inaccurate predictions of
the start of menses may have affected the observed re-
sults [12] but is likely reflective of real-world use;
nVNS has the flexibility to be used outside the peri-
menstrual period (e.g., before or after menstruation)
without increasing the potential for medication-
related AEs and complications.
The relative refractoriness of MM/MRM attacks to
pharmacologic treatments currently available (but not
specifically approved) for the condition [10] may be re-
lated to the complexity of the relationship between mi-
graine and oestrogen and the brain’s sensitivity to
fluctuations in hormones that cross the blood–brain
barrier [27]. Chronic exposure to oestrogen has been
suggested to enhance susceptibility to migraine by pro-
moting increased numbers and excitation of glutamatergic
neurons [28]. Paradoxically, oestrogen withdrawal is asso-






























Fig. 4 Change in HIT-6™ Migraine Disability (ITT Population)a. Abbreviations: HIT-6, 6-item Headache Impact Test; ITT, intention-to-treat; nVNS,
non-invasive vagus nerve stimulation; SEM, standard error of the mean. aData are mean ± SEM; mean differences between treatment groups may
not reflect calculated differences because of rounding; P values are from the t test; missing data were imputed using the last observation carried
forward. bOne subject had missing HIT-6 data for both the baseline and nVNS periods
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The efficacy of nVNS in the treatment of migraine may be
related to the suppression of excessive extracellular levels
of glutamate [29]. In MM/MRM, prophylactic nVNS may
exert its anti-glutamatergic mechanistic actions directly
via the trigeminal nociceptive pathways of women who
are susceptible to oestrogen-related attacks.
The efficacy of prophylactic medications used for
MM/MRM has been demonstrated in clinical trials
[30, 31] but may be limited by oestrogen level declines
and by concerns related to rebound headaches, practi-
cality, and safety. Managing optimal oestrogen levels is
challenging for many clinicians, especially in the
context of orally administered drugs, because of the
complex changes that occur throughout the menstrual
cycle [27]. Randomised, double-blind, placebo-controlled
MM/MRM studies have suggested that prophylactic trip-
tan and perimenstrual oestrogen therapy may lead to
post-treatment or rebound migraine attacks [32–34],
possibly reflecting a delayed abrupt decrease in
oestrogen levels upon medication discontinuation or a
nonhormonal occurrence of end-menstrual migraine (i.e.,
related to blood loss and transient relative anaemia) [35].
Rebound attacks were not observed after nVNS discon-
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Fig. 5 Change in MIDAS Migraine Disability (ITT Population)a. Abbreviations: ITT, intention-to-treat; MIDAS, Migraine Disability Assessment; nVNS,
non-invasive vagus nerve stimulation; SEM, standard error of the mean. MIDAS score (a) and MIDAS grade (b). aData are mean ± SEM; mean
differences between treatment groups may not reflect calculated differences because of rounding; P values were from the t test; missing data were
imputed using the last observation carried forward. bOne subject had missing MIDAS grade data for both the baseline and nVNS periods
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primary headache conditions [16–19], but additional stud-
ies are needed to rule out the potential for post-nVNS
migraines. Patients with MM/MRM may be reluctant
to accept these and other AE-related consequences of
preventive triptans given the potentially modest thera-
peutic gain [12, 15, 32]. The oral anticonvulsant topira-
mate has been shown to be effective in the prevention
of MM attacks but does not appear to reduce attack
severity or duration [36]. In addition, topiramate may
require several months of daily administration to
achieve its potential benefits and may increase the risk
for serious adverse events [36, 37]. Non-invasive vagus
nerve stimulation is a practical nonpharmacologic op-
tion that does not affect oestrogen levels, interact with
acute medications, or increase cardiovascular disease
risk. Results of the current study suggest that prophy-
lactic nVNS reduces medication use in women with
MM/MRM, thereby possibly mitigating the future risk
of medication overuse headache and chronic migraine
[13, 16, 38].
Non-invasive vagus nerve stimulation may serve as an
effective therapeutic option with no safety or tolerability
concerns for MM/MRM prevention and may mitigate
the risk of medication-related AEs and complications,
rebound headaches, and potential drug interactions that
are highly relevant among this population. Prophylactic
use of nVNS for up to 14 days per month is practical
and appears to provide a clinical benefit in MM/MRM
while decreasing the need for analgesic medications,
consistent with results of previous nVNS studies of
other primary headache disorders [16–19].
Conclusions
This study suggests that mini-prophylaxis with nVNS is
an effective treatment that reduces the number of MM/
MRM days and acute analgesic use for subjects with
MM/MRM without adding any treatment-related safety
or tolerability concerns. The current study also expands
the body of evidence regarding this condition, for which
there are no specifically approved therapies. As the first
neuromodulation technique evaluated in patients with
MM/MRM, nVNS may offer an important new option
for effectively treating the condition while mitigating the
monthly perimenstrual AE burden and potential compli-
cations of pharmacologic medications. Randomised con-
trolled studies are needed to validate these results.
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